Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Rhea-AI Summary

Jasper Therapeutics (Nasdaq: JSPR), a biotech company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases, has announced its participation in three upcoming investor conferences in September 2024:

1. H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, fireside chat on Sept 10 at 3:00 p.m. ET)
2. 2024 Cantor Fitzgerald Healthcare Conference (Sept 17-19, fireside chat on Sept 17 at 2:30 p.m. ET)
3. TD Cowen Chronic Urticaria Summit (Sept 20, fireside chat at 12:00 p.m. ET)

Live webcasts of the presentations will be available on Jasper's Investor Relations website, with archived replays accessible for 30 days after the live broadcasts.

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September:

H.C. Wainwright 26^th Annual Global Investment Conference
Conference Dates: September 9-11, 2024
Presentation Date/Time: Tuesday, September 10, 2024, 3:00 p.m. ET
Presentation Format: Fireside Chat

2024 Cantor Fitzgerald Healthcare Conference
Conference Dates: September 17 – 19, 2024
Presentation Date/Time: Tuesday, September 17, 2024, 2:30 p.m. ET
Presentation Format: Fireside Chat

TD Cowen Chronic Urticaria Summit
Conference Date: September 20, 2024
Presentation Date/Time: Friday, September 20, 2024, 12:00 p.m. ET
Presentation Format: Fireside Chat

Live webcasts of the presentations will be available on the Events & News – Events page of Jasper's Investor Relations website. An archived replay of the presentation will be available on Jasper's website for 30 days following the live broadcast.

About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria, asthma and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper’s presentations at the H.C. Wainwright Annual Global Investment Conference, Cantor Fitzgerald Healthcare Conference and TD Cowen Chronic Urticaria Summit, and briquilimab’s potential to address mast cell driven diseases such as CSU, CIndU and asthma. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com

Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com

FAQ

What investor conferences will Jasper Therapeutics (JSPR) attend in September 2024?

Jasper Therapeutics will attend three investor conferences in September 2024: H.C. Wainwright 26th Annual Global Investment Conference, 2024 Cantor Fitzgerald Healthcare Conference, and TD Cowen Chronic Urticaria Summit.

When is Jasper Therapeutics (JSPR) presenting at the H.C. Wainwright Global Investment Conference?

Jasper Therapeutics will present at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 3:00 p.m. ET in a fireside chat format.

What is the presentation format for Jasper Therapeutics (JSPR) at the September 2024 investor conferences?

Jasper Therapeutics will participate in fireside chat presentations at all three September 2024 investor conferences.

How can investors access Jasper Therapeutics' (JSPR) presentations from the September 2024 conferences?

Live webcasts of Jasper Therapeutics' presentations will be available on the Events & News – Events page of the company's Investor Relations website. Archived replays will be accessible for 30 days following the live broadcasts.

What is the main focus of Jasper Therapeutics' (JSPR) drug development?

Jasper Therapeutics is focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.